Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UKResearch in context

Summary: Background: Patients with advanced or recurrent endometrial cancer have poor survival outcomes because effective treatment options remain limited. We investigated the efficacy and safety of cediranib plus weekly paclitaxel or olaparib versus weekly paclitaxel alone after prior platinum-bas...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন

প্রধান লেখক:	Robert D. Morgan, Catharine Porter, Cong Zhou, Rebecca Kristeleit, Sudha Desai, Ignacio Vazquez, Angela George, Gemma Eminowicz, Axel Walther, Adrian Franklin, Azmat H. Sadozye, Andrew Hughes, Louise Hanna, Rene Roux, Rosemary Lord, Rebecca Bowen, Joey Wood, Clara Sentamans, Ann White, Angela C. Casbard, Alys Humphrys, Jennifer B. Swettenham, Lisette S. Nixon, Richard Adams, Ruby Ray, Elena Brogden, Wendy E. Powell, Joanna Canham, Tracy M. Cox, Monica Narasimham, Helen Lowe, Leah Ensell, Mohammed Zubair, Karen Morris, Molly Glenister-Doyle, Ariadna Fuertes Gassio, Derrick Morgan, Dylan Broughton, Margherita Carucci, Phillip J. Monaghan, Jonathan Tugwood, Richard J. Edmondson, Caroline Dive, Gordon C. Jayson, Andrew R. Clamp
বিন্যাস:	Artigo
ভাষা:	Inglês
প্রকাশিত:	Elsevier 2026-06-01
মালা:	EClinicalMedicine
বিষয়গুলি:	Clinical trial Endometrial cancer Paclitaxel Cediranib Olaparib Plasma Tie2
অনলাইন ব্যবহার করুন:	http://www.sciencedirect.com/science/article/pii/S2589537026002610
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!